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Chapter One
Introduction
General features of Influenza viruses and infections:
Nearly 700,000 people are hospitalized annually due to influenza virus infections
in the United States alone, with outbreaks causing between 12,000 and 56,000 deaths
every year (Maggie Fox, 2018). These numbers do not always include those who die
from other complications associated with the virus such as diabetes and cardiovascular
disease. The virus is spread in small droplets via cough, sneeze, or touch, which can
infect individuals (Influenza (Flu), 2018). First or second hand contraction can occur by
someone sneezing, causing the droplets to enter your mouth/nose (Influenza (Flu),
2018). Additionally, the virus can exist on contaminated surfaces therefore leading to
possible infection if touched. Once the virus enters your body, immediate action must
be taken by your immune system to defend its host. The immune system responds by
sending white blood cells, such as T cells and other inflammatory molecules such as
cytokines, to attack the virus (Jabr, 2017). The main part of the body where the virus
resides is in the lungs/respiratory tract. If the immune system responds properly, the
virus should be cleared from the host and recovery takes approximately one week. If
the immune system responds too aggressively, the inflammatory molecules produced
can destroy too much lung tissue, causing the lungs to be incapable of delivering the
proper amount of oxygen to the blood, leading to death (Jabr, 2017). Other secondary
complications such as bacterial pneumonia, encephalitis, and myocarditis are very
dangerous as well. This is why the development of a universal flu shot is critical, with its
ability to save millions of lives.
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The CDC categorized influenza into five different categories: seasonal, avian,
swine, variant, and pandemic (Influenza (Flu), 2018). It is also broken down into 4
different virus types: A, B, C and D. Due to the different categories and viruses
circulating at any given time, the vaccine is constantly changing each year. Scientists
and researchers review and study the vaccine composition annually hoping to protect
as many people as possible. The CDC, the FDA, physicians, pharmacists, and nearly
all other experts agree that the most effective way to combat this disease is through the
influenza vaccine. In Dr. Huber’s laboratory I was able to test the ability of a universal
influenza vaccine candidate to induce antibodies against both human and swine viruses
using hemagglutination inhibition assays.
Vaccine-induced immunity against influenza viruses:
Hemagglutination inhibition assays (HAI assays) are used to detect and quantify
the concentration of antibody in serum and rely on the natural ability of influenza viruses
to bind red blood cells through a process known as hemagglutination. The HAI assay is
the gold standard for antibody detection against these viruses. HAI assays are used to
show if an influenza virus causes hemagglutination in blood, or if antibodies present in a
sample can inhibit hemagglutination. Influenza viruses are composed of a glycoprotein
envelope that can bind to sialic acid molecules found on the sialic acid residues that
serve as receptor sites on red blood cells (Racaniello, 2009). Usually when red blood
cells are put into a saline solution the cells will gradually drop to the bottom of a tube
due to gravitational forces, appearing as a red dot. However, when viruses are added
to the solution, interactions between the virus and red blood cells may be seen. The red
blood cells are prevented from falling to the bottom on the tube and instead a shield is
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formed keeping the cells suspended (Racaniello, 2009). This can be seen as a foggy
red liquid rather than a single red dot (Figure 1). If a patient's serum contains
antibodies that block viral attachment to red blood cells, this interaction is inhibited, and
the red blood cells will settle to the bottom of the tube in a manner that looks like virus is
not present. Influenza viruses are highly specific to the antibodies used within HAI,
making the use of this method highly effective for antibody detection. The assay can be
easily modified to determine the level of antibodies against influenza virus that are
present in serum samples, with pig and mouse serum being among some of the most
popular sera samples to test for antibodies after vaccination. In this study, I used the
HAI assay to test specific influenza viruses against sera taken from animals that were
vaccinated with an H1N1 universal vaccine candidate.
Every influenza season is different, with variants of the influenza A and B types,
notably represented by the influenza A subtypes H1N1 and H3N2, circulating every
season. This makes matching the vaccine with the circulating variant nearly impossible.
The traditional trivalent vaccine (annual vaccine) protects against H1N1 (Influenza A),
H3N2 (Influenza A), and influenza B virus, while the quadrivalent vaccine includes an
additional influenza B virus (CDC, 2018). In 2009 we saw a novel variant of the H1N1
virus spread around humans causing a global pandemic. This virus contained swine,
human, and avian genetic components, and was vastly different from the variants that
circled during the past 30 years. This meant that the novel virus and the vaccine did not
match, leading to more incidences of influenza, which coincided with increases in
hospitalization rates and deaths. Since the immune system of children are naïve, and
the immune systems of elderly are weak, both populations are more vulnerable to
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severe influenza virus infections and are at a higher susceptibility to death (Jabr, 2017).
However, despite these hospitalization rates, in 2009, young adults were the group that
was most affected by this novel H1N1 virus that replaced the seasonal H1N1 variant
that was previously circulating (Jabr, 2017). A seasonal vaccine against this novel
variant still remains the gold standard of protection against influenza. Since matching
each variant on an annual basis is also very time consuming (Gerdil C., 2003), broad
immunity may be a possibility in the future. However, the annual changes that occur as
influenza escapes host immunity makes induction of broad immunity very difficult. In
order to increase the breadth of immunity induced, a DNA shuffling strategy was
proposed as a potential solution.
Can we create a vaccine that induced immunity against multiple H1N1 variants?:
DNA shuffling is a process of randomly recombining parental genes to create a
novel gene that expresses a protein containing desired properties of the individual
parental genes (Joern, J. M., n.d.). In our case, DNA shuffling is being used to create a
single protein that can induce immunity against 4-5 parental influenza A H1N1 variants.
This is very important for influenza viruses because they can cross a species barrier,
which was the case in 2009. The novel H1N1 variant, also known as the swine flu, had
the ability to move freely between pigs and humans (Berlanda Scorza, F., et al., 2016).
The method used in the Huber lab induces immunity against the HA protein using
epitopes, which are the part of an antigen molecule to which an antibody attaches itself.
This method is intended to both prevent transmission between pigs and humans, and
stop virus spread among pigs and among humans. The approach could be utilized to
create a pre-pandemic vaccine that would also be useful during the early stages of a
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pandemic. If we can prevent the virus from circulating within the swine population, this
may ultimately mean a decrease in transmission from pigs to humans as well.
Previous work in the Huber lab showed that recombined chimeric genes created
by DNA shuffling can attain the properties described above. Specifically, a single
protein had the ability to induce antibodies against 4-5 parental variants (McCormick, et
al., 2015). These “desired genes” specifically contain influenza A virus hemagglutinin
(HA) sequences and the ability to induce antibodies was evaluated in both mouse and
pig models (McCormick, K., et al. 2015). Molecular breeding can speed up the
evolution of a virus (Crameri A, Raillard, 1998), and this was the method used to create
the previous vaccine against influenza A in pigs. One restriction of the vaccine
produced was that only one of the HA’s could be expressed within a conventional
vaccine, and this HA was known as HA-129. However, screens that were done using
DNA vaccines for all of the chimeric HAs produced showed that one additional geneshuffled products, HA-113, could induce immunity with increased breadth and strength,
compared to HA-129. Although we were unable to express HA-113 using conventional
vaccine methods that were available in the Huber lab, we were able to utilize the
parainfluenza virus 5 (PIV-5) technology that was available through collaboration with
Biao He (University of Georgia, Athens, GA). PIV-5 was used as a vector for delivery of
influenza hemagglutinins created using DNA shuffling as universal vaccine candidates
(Figure 2), specifically the HA-111 and HA-113 genes.
Parainfluenza virus-5 (PIV-5) as a vaccine vector:
Many viruses can enter though the respiratory tract. This includes the influenza
virus, paramyxoviruses, coronaviruses, pox viruses and herpes viruses (Clark, K. M., et
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al. 2011). Paramyxoviruses can infect the respiratory tract and cause a wide variety of
human and animal diseases (Welch BD, et al., 2013). We have chosen PIV5 as a
vector for vaccine delivery based on a number of characteristics of this paramyxovirus.
First, the vaccine has been demonstrated as safe as it was tested in a live vaccine
against kennel cough in dogs. No adverse events were reported. Additionally, PIV5based vaccines will not interfere with prior immunity against PIV5 (Chen Z., 2012 ).
Lastly, PIV5 vectors can induce immunity against different influenza A virus subtypes in
mice, thus PIV-5 is a viral vector that is a promising candidate for vaccine development
(Li Z., et al., 2013). With this information, PIV5 was utilized as our vector for influenza
HAs, and here we report on the testing of a PIV5 expressing HA-113 (PIV5-113) in both
mice and pigs. This PIV5-113 vaccine induced broad immunity in both animal models,
with quantifiable readouts being detection of antibodies and the ability to protect against
virus infection. The findings are presented below and discussed in the context of how
broad vaccine-induced immune responses can prevent both seasonal and, potentially,
pandemic influenza virus infections.
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Chapter Two
Methods and Materials
Parental HA Genes
The HA genes of parental H1N1 influenza A viruses, including A/Tennessee/1560/09 (TN09), A/NewJersey/8/1976 (NJ76), A/Ohio/01/2007 (OH07), and
A/Iowa/01/2006 (IA06) were isolated from stock viruses and cloned as described
(McCormick, et al., 2015). Additional H1N1 influenza A virus strains, were used to test
antibodies induced for cross reactivity, as described below. Viruses expressing TN09,
NJ76, OH07, and IA06 HA proteins were used to determine the reactivity of HA-113induced antibodies against the parental viruses. The primary viruses expressing HA
proteins from the A/Germany/81, A/Iowa/92, A/Brisbane/07, A/California/09,
A/Michigan/15, and A/swine/Iowa/13E100/2013 were used to test the breadth of
immunity induced by the vaccine candidate. A/Brisbane/59/2007 HA is antigenically
similar to the A/Memphis/3/2008 HA, and both of these viruses circulated in humans
immediately prior to the H1N1 pandemic in 2009. Additionally, the A/Michigan/2015
virus represents the H1N1 variant that was included in the 2017 human vaccine,
replacing the A/California/4/2009 isolate that had been in the vaccine since 2009. The
A/swine/Iowa/13E100/2013 virus was isolated from a nasal swab taken from a healthy
pig in Iowa in May of 2013. The A/Michigan/2015 virus and the
A/swine/Iowa/13E100/2013 virus are particularly crucial in the evaluation of our PIV5113 vaccine because these viruses were both isolated after the 2009 pandemic. Since
2009 was the last year for inclusion of a parental HA in the vaccine, these viruses are
being used to determine whether the vaccine can induce immunity against future human
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(Michigan) and swine (13E100) viruses that circulated in their populations after the
vaccine had been created by DNA shuffling.
Creation of PIV-113
Using sequences from previously shuffled genes (McCormick, et al., 2015). Biao
He created PIV5 vaccine expressing HA-113 (PIV5-113). This was done by expressing
the DNA sequence from the shuffled HA gene HA-113 (McCormick, et al., 2015) in PIV5
(ZL48 virus) between the genes expressing hemagglutinin-neuraminidase (HN) and the
large RNA polymerase (L) proteins (Mooney AJ., 2013).
Vaccination using PIV5-113
Using PIV5 expressing HA-113 (PIV5-113) as a vaccine, post-vaccination sera
samples were taken on days 7, 14, 21, and 28 and tests were performed to monitor
antibody production. Mice were immunized with PIV5-113 and then given a booster on
day 28 and sera were collected three weeks later. Pigs were immunized with PIV5-113
and given a booster 14 days later. After vaccination, pigs and mice were challenged
with influenza viruses and nasal swabs were taken on day 1 post challenge, day 3 post
challenge, and day 5 post challenge. Tests including the HAI assay, as described
below, were performed. Focusing on HAI assays, the sera samples provided sufficient
data to show antibody production against parental influenza strains. In this study we
evaluated vaccine-induced immunity using PIV5 expressing HA-113 (PIV5-113) using
both mouse and pig models of vaccine:challenge. As a control, the vector alone (PIV5
alone) was delivered to both mice and pigs.
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Hemagglutination Inhibition Assay (HAI)
Hemagglutination inhibition (HAI) assays were performed to evaluate antibody
levels in the sera collected (Figure 1). The highest dilution of serum that prevents
hemagglutination is called the HAI titer for that serum sample (Acharya, 2018). To
perform the HAI assay the virus is diluted across a 96-well, round-bottom plate (50μl
PBS to columns 2-13, 100μl virus in the 1st column). A solution of 0.5% red blood cells
in 50 microliters is then added to each well to determine the amount of virus present.
After 30 minutes, hemagglutination can be observed. The virus stock is diluted to a 1:8
titer in 50 microliters and tested to confirm a titer of 1:8 using the dilution system
described above. Once the virus stock is at a 1:8, it can be used in the HAI assay to
determine whether the antibody present in the serum can inhibit virus interactions with
red blood cells.
For the HAI assay, a round-bottom 96-well plate is used, and 25 microliters of
PBS is added to each well with the exception of the first well in a row or column
(depending on the dilution scheme). Mouse and pig sera that are used in the HAI assay
are initially treated with RDE, heat inactivated, and pre-cleared with red blood cells to
remove natural inhibitors to the assay, as described (McCormick, et al., 2015). After
treatment, serum samples are added to the first well in a 50 microliter volume and
diluted as described above for virus, using 25 microliters as the transfer volume
between wells. After the sera have been diluted, 25 microliters of virus (4
hemagglutinating units, based on the 1:8 titer in 50 microliters that was determined
previously) is added to each well. Plates containing diluted antibody and virus are
incubated for an hour before adding 50 microliters of 0.5% red blood cells. After 30
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minutes the HAI titer can be observed and recorded. Since antibodies against influenza
HA have the ability to prevent attachment of the virus to the red blood cells, the highest
dilution of serum that prevents hemagglutination (hemagglutination inhibition) is called
the HAI titer of the serum (Racaniello, 2009). Titers are reported as the reciprocal of the
final serum dilution that inhibits hemagglutination. A titer 5 is assigned to serum
samples that did not demonstrate HAI at the starting dilution of 1:10. HAI assays were
performed on both mouse and pig serum.
Mouse Challenge
Mice were immunized with PBS, PIV5, or PIV-113. They were given a second
dose of their respective vaccine 28 days later as a boost, and sera were collected 20
days after this second inoculation. Mice were challenged with mouse-adapted viruses
expressing the parental HA’s from A/Tennessee/1-560/09 (TN09), A/NewJersey/8/1976
(NJ76), A/Ohio/01/2007 (OH07), and A/Iowa/01/2006 (IA06), and A/Memphis/3/2008
(ME08). These viruses were created as described previously (McCormick, et al., 2015),
and mouse challenge studies were performed as described (Huber, 2009).
Pig Challenge
Pigs were immunized with PBS, PIV5, or PIV-113 and boosted with their
respective vaccines on day 14. Sera were collected 14 days later and challenged with
the viruses. Nasal swabs were taken on day 1 post challenge, day 3 post challenge,
and day 5 post challenge. These viruses were created as described previously
(McCormick, et al., 2015).
Ethics Statement

13
All work performed with influenza viruses was done in accordance with protocols
that were approved by the Institutional Biosafety Committee of the Unviersity of South
Dakota (USD) and Kansas State University (KSU). Work in mice was done following
experimental conditions approved by the Institutional Animal Care and Use Committee
(IACUC) of USD, while work in pigs followed IACUC-approved procedures established
at KSU.
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Chapter Three
Results

In this study, both mice and pigs were vaccinated with a Parainfluenza Virus
(PIV-5) vector that expressed HA-113 (PIV5-113, Figure 2). I will first discuss the
results found with the challenge in mice, which was work that was completed by Sarah
Zaiser before I joined the Huber lab, and then I will discuss the results for the vaccine
and challenge of pigs, which was done by Ying Fang at Kansas State University
(Manhattan, KS). My specific role in this study was to use the HAI method to test and
determine the antibodies induced after vaccination in both mice and pigs. The complete
results are being presented as a way to relay the contribution of my work in the big
picture of the project.
Mice vaccinated with PIV5-113 demonstrated immunity against individual
influenza viruses that expressed HA proteins from all 5 parental viruses (Figure 3). All
of the PIV5-113 vaccinated mice that were challenged with NJ76-, IA06-, OH07-, and
TN09-expressing, mouse-adapted viruses showed protection against the lethal
challenge, while none of the mice challenged with the ME08-expressing virus survived
(Figure 4). This means that although antibodies were induced against ME08 by the
PIV5-113 vaccine, the levels were not high enough to provide protective immunity. The
gold standard for protective immunity against influenza infection is an HAI titer of 40,
which is a titer that is defined for population studies. It is known that 50% of people that
have a titer of 40 will be protected from virus infection, but individuals may vary in the
relationship between antibody titer and protection against infection. ME08 had an
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average titer of approximately 20, which was not strong enough to provide protection
against this virus.
Since immunity was achieved in the mice using the novel PIV5-113 vaccine, a
vaccine:challenge study was performed in pigs. Pigs are a more closely related species
to humans and pandemics arise from swine, making them a vital tool in vaccine
research and an important population to test our vaccine. In fact, the PIV5-113 vaccine
has the ability to be mass-produced and used directly in pigs, if it can demonstrate
value in pilot studies like this. Pig serum samples from PIV5-113-vaccinated animals
were tested for their reactivity against viruses expressing NJ76, IA06, OH07, TN09 and
ME08 HA proteins. Results show an antibody response against all viruses except
ME08 once again (Figures 5 and 6), which is not surprising since immunity against this
virus did not reach a titer of 40 in mice either. Similar to the results in mice, we would
predict that challenge of pigs with viruses expressing NJ76, IA06, OH07, and TN09
would be protective. Meanwhile, a challenge with a virus expressing ME08 would not
show protection since it had a titer of approximately 20. These results show that our
PIV5-113 vaccine could induce immunity in pigs similarly to what was observed in mice.
To determine whether PIV5-113 could induce broad immunity in pigs, we
performed HAI assays using non-parental viruses expressing HA proteins from the
IA92, CA09, MI15, GE81, BR07, and 13E100 viruses (Figure 7). These viruses are
from the H1N1 family, and many were used in our previous study to demonstrate the
breadth of immunity induced in pigs with the HA-129 vaccine (McCormick, et al., 2015).
These were chosen because they are viruses that circulate in both pigs and humans,
including viruses that circulated after our vaccine was created. The results show that
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viruses expressing the BR07 and GE81 HAs had HAI titers that were less than 40,
similar to the ME08 virus. Once again this would predict an inability for our vaccine to
protect against direct challenge with these viruses. However, HAI titers against CA09,
which was the H1N1 isolate included in vaccines starting in 2009 and is closely related
to TN09, were similar to those detected against NJ76, IA06, OH07, and TN09,
predicting protection. Interestingly, the MI15 and 13E100 viruses that represent viruses
circulating in humans in 2015 and pigs in 2013 reacted with antibodies induced by PIV5113 vaccines, showing that the PIV5-113 vaccine could provide immunity against
influenza viruses that circulated in pigs and humans after its creation in 2009. This
shows an added value of our vaccine. It indicates that with updates, a higher titer may
be able to be achieved against all of these viruses. Since both Cal09 and MI15 had
titers over 40, the PIV5-113 vaccine has potential as a candidate vaccine for current
and future vaccines. In the future we will continue to test viruses post 2009 pandemic to
provide more information related to virus evolution away from the breadth of protection
provided by PIV-113.

17
Legend

Figure 1: This figure shows hemagglutination versus hemagglutination inhibition
as described in the methods and materials section (Acharya, 2014). Since antibodies
against influenza HA have the ability to prevent attachment of the virus to the red blood
cells, the highest dilution of serum that prevents hemagglutination (hemagglutination
inhibition) is called the HAI titer of the serum (Racaniello, 2009).
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Figure 2: This figure shows how an HA expressing virus (novel HA) was created,
PIV5-113. Biao He created PIV5 vaccine expressing HA-113 (PIV5-113) using
previously shuffled genes. PIV5 was utilized as a vector as described in method and
materials. Picture provided by Biao He.
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Figure 3: The data above shows the reactivity of sera from pigs vaccinated with
HA-113. Reactivity against parental HAs is shown. The number of mice per vaccine
group were as follows: 20 mice for PBS, 40 mice for PIV5, and 39 mice for PIV5-113.
Data provided by Sarah Zaiser.
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Figure 4: This graph shows the influenza vaccine:challenge study in mice. Protective
immunity established. The numbers of mice per challenge were as follows: 4 per
challenge for PBS, 8 per challenge for PIV5, and 7-8 per challenge for PIV5-113. Data
provided by Sarah Zaiser.
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Figure 5: This graph shows the influenza vaccine:challenge study in mice. Protective
immunity established. The numbers of mice per challenge were as follows: 4 per
challenge for PBS, 8 per challenge for PIV5, and 7-8 per challenge for PIV5-113. Data
provided by Sarah Zaiser.
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Figure 6: HAI assay results after vaccination in pigs. There were 6 pigs per vaccine
group. ME08 showed no antibody detection, but NJ79, IA06, OH07 and TN07 all had
antibody detection after vaccine delivery.
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Figure 7: HAI assay results after vaccination in pigs. There were 6 pig per vaccine
group. IA92, CA09 and MI15 all had antibody detection after vaccine delivery, but BR07
and GE81 did not.
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Chapter Five
Discussion and Summary
Currently influenza prevention depends on predicting which variants of the virus
will circulate throughout the year and then creating vaccines that protect against those
variants. The World Health Organization is responsible for selecting three strains that
will resemble the ones circulating during influenza season in the Northern and Southern
hemispheres (CDC, 2018). Pandemics (antigenic shift) and epidemics (antigenic drift)
can be misinterpreted, and we have been poorly prepared for these situations when
they arise. Our PIV5-113 vaccine provides sufficient data to give hope to the possibility
of a universal influenza vaccine. This single vaccine induced immunity against
influenza viruses that circulated in pigs and humans both before and after the novel
H1N1 virus that caused a pandemic in 2009. With its creation, and successive
improvements in both design and immunogenicity, pandemic and epidemic influenza
infections can be prevented.
Pandemics represent a more rapid and dramatic change in the genetic makeup
of viruses through re-assortment of the individual virus genes, and they usually come
from a known source, such as another species like pigs or birds. When influenza
viruses cross from animals to humans, novel or “pandemic” stains are be generated
(Berlanda Scorza, F., et al., 2016). According to the CDC, “An influenza pandemic is a
global outbreak of a new influenza A virus. Pandemics happen when new (novel)
influenza A viruses emerge which are able to infect people easily and spread from
person to person in an efficient and sustained way” (Pandemic Influenza, n.d.).
Alternatively, epidemics arise through an accumulation of point mutations that arise as
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the virus evolves to escape adaptive immunity and they lead to annual vaccine
changes.
In cases like the 2009 H1N1 influenza pandemic, a vaccine might need to be
created after the strains for the season have already been selected (Huber VC, et al.,
2009). Based on the statistics for deaths and hospitalization provided by the CDC, the
method currently used is clearly not very efficient, especially during the initial wave of a
pandemic. Viruses in birds and pigs can be studied before they emerge in humans. If
this knowledge is available, a pre pandemic vaccine can be created. Using PIV5 and
creating an HA like HA-113, which was created using DNA shuffling, broad immune
responses can be induced. Four phylogenetic clades were represented by the chosen
parental influenza A H1N1 strains, covering those known to circulate in pigs. HA genes
of these parental strains (NJ76, IA06, OH07, ME08, and TN09) were used for DNA
shuffling and here we evaluated the HA-113 chimeric construct created. PIV5 was
utilized as a vector for expression of this candidate chimeric HA protein. The data
presented here show that HA-113 expressed in PIV5 can induce immunity against HA
proteins representing parental HAs that are included within the DNA-shuffled sequence
and that the PIV5-113 vaccine induced antibody titers at levels that protected against
NJ76, IA06, OH07, and TN09 virus infections. Antibodies were also induced against
ME08 when the PIV5-113 vaccine was used, but these did not protect against challenge
with an ME08-expressing virus. It is worth noting that this virus circulated in humans
prior to 2009 and was much different than the other viruses used in DNA shuffling.
It may be possible to create a universal vaccine using DNA shuffling, which
creates recombined chimeric HA proteins. By incorporating HA epitopes from swine
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and human influenza viruses into the vaccine, this could be utilized as a pre pandemic
vaccine to decrease the amount of people infected with this virus. The HA epitopes
should allow the vaccine-induced antibodies to recognize the circulating virus and allow
for the recognition of viruses that evolve later. The prime example of this is how PIV5113 induced antibodies against a virus isolated from pigs in 2013 (13E100) and the
human virus from 2015 (MI15). This indicated that the immunity against the evolved
HAs is maintained by the chimeric HA vaccine. By creating a vaccine that can prevent
the virus from circulating around the swine species, this could lessen the chances of a
pandemic like the one that occurred in 2009.
According to the CDC, “Improved surveillance of influenza in pigs and other
animals may help to detect the emergence of influenza viruses with the potential to
cause illness and spread among people, possibly resulting in a pandemic. Early
detection of such viruses can alert public health officials and aid in pandemic
preparedness through the development of appropriate diagnostic tests and influenza
vaccine candidate viruses, if necessary” (Origin of 2009 H1N1). By using DNA
shuffling, we were able to create a vaccine that induced enough antibodies to provoke
an immune response.
Creating chimeric HA’s of the H1N1 subtype via DNA shuffling is a much more
proactive solution than the current method. Since the HA construct showed
immunogenicity in both mice and pigs, it is hypothesized that it could induce protective
immunity amongst the circulating variants in humans. The MI15 virus, which is a virus
from 2015 that was isolated after the 2009 epidemic, was recognized by antibodies
induced by PIV5-113. This indicates that other viruses from after 2009 should be tested
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to see where and when the degree of PIV5-113 reactivity ends. If a vaccine is
developed using this approach, pandemics will hopefully be avoided, and vaccines
could target both pigs and humans to limit interspecies transmissions that are
associated with pandemics. In the DNA-shuffling approach a new chimeric HA can be
created and tested when the PIV5-113 no longer induces sufficient antibodies.
In summary, the current method of developing vaccines is too slow to prevent
pandemics (Robertson JS, et al., 2011), but the PIV5-113 vaccine tested here showed
antibody responses in mice pigs that predict similar performance in humans. This
means that a vaccine like PIV5-113 may limit transmission events between pigs and
humans, which would be important either before a pandemic or early during the
pandemic. If this would have been available in 2009, the pandemic could have been
lessened or avoided completely. Hopefully my work in Dr. Huber’s laboratory
contributes to the possibility of developing a universal vaccine with broad immunity.
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